Abstract: The glycoprotein B ("gB") and functional fragments thereof are provided by recombinant DNA technology. Oligonucleotide sequences are provided coding the glycoprotein, its precursor and fragments thereof. Methods and compositions are disclosed for the production of the glycoprotein and functional fragments thereof as well as oligonucleotide sequences, which may be used for probes or other applications, and particularly may be used for vaccines. The following E. coli HB101 strains were deposited at the A.T.C.C. on April 4, 1984, where the plasmid indicates the plasmid employed to transform the strain; pHS112; pHS114 (gB1 mammalian); pHS127A (gB1 yeast); pHS203; and pHS206 (gB2), and assigned Accession Nos. 39649-39653, respectively, where the nature of the plasmid is indicated in parentheses and the number refers back to the number employed in the Experimental section.
Type:
Grant
Filed:
September 20, 1990
Date of Patent:
September 14, 1993
Assignee:
Chiron Corporation
Inventors:
Rae L. Burke, Carol Pachl, Pablo D. T. Valenzuela
Abstract: A new receptor for fibroblast growth factor has been cloned and expressed. The recombinant receptor is useful for inhibiting FGF activity, and for screening compounds for binding activity similar to that of FGF. A soluble, truncated recombinant receptor is also prepared, and is capable of binding FGF.
Type:
Grant
Filed:
January 11, 1991
Date of Patent:
July 20, 1993
Assignee:
Chiron Corporation
Inventors:
Michael C. Keifer, Pablo D. T. Valenzuela, Philip J. Barr
Abstract: DNA encoding two forms of PDGF A-chain polypeptide, the construction of expression vectors for expressing such DNA in yeast and mammalian cells, and the expression of such DNA in yeast and mammalian cells to produce active PDGF A-chain homodimer and active PDGF A-chain/B-chain heterodimer are disclosed.
Type:
Grant
Filed:
August 27, 1990
Date of Patent:
June 15, 1993
Assignee:
Chiron Corporation
Inventors:
Carl-Henrik Heldin, Christer Betsholtz, Bengt Westermark, Timothy J. Knott, James Scott, Graeme I. Bell
Abstract: A purified binding protein selected from the group consisting of insulin-like growth factor binding protein having an amino acid sequence which is at least 85% homologous to the amino acid sequence of FIG. 1 and fragments thereof comprising at least 10 consecutive amino acids of the sequence that are capable of binding to an antibody specific for the protein or to an insulin-like growth factor is described. Recombinant DNA molecules encoding the binding proteins and subsequences thereof are also described along with recombinant microorganisms and cell lines containing the DNA molecules and methods for preparing the binding proteins by growing the recombinant hosts containing the relevant DNA molecules. Antibodies to the protein, identified as IGFBP-6, which are useful in various diagnostic applications, are also described.
Abstract: The nucleotide sequence of the genome for bovine diarrhea virus (BDV) is disclosed. The sequence permits design and construction of vaccines effective against BDV.
Type:
Grant
Filed:
July 6, 1990
Date of Patent:
April 27, 1993
Assignee:
Chiron Corporation
Inventors:
Andre Renard, Dino Dina, Joseph Martial
Abstract: Vaccines and therapeutic compositions and methods for their production and use against Herpes Simplex Virus (HSV) are provided employing recombinant HSV glycoproteins B and D.The following E. coli HB 101 strains were deposited at the A.T.C.C., where the plasmid indicates the plasmid employed to transform the strain; pH203; pHS112; pHS114; pHS127A and pHS206 were deposited on Apr. 4, 1984, and assigned Accession Nos. 39649-39653, respectively; pYHS109 and pYHS118 were deposited on Jul. 11, 1984, and given Accession Nos. 39762 and 39763, respectively.
Type:
Grant
Filed:
October 2, 1989
Date of Patent:
December 15, 1992
Assignee:
Chiron Corporation
Inventors:
Rae L. Burke, Carol Pachl, Pablo D. T. Valenzuela
Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
Abstract: A method for preventing or ameliorating HSV infection in a bird or mammal comprises administering a composition comprising an effective amount of an HSV surface glycoprotein and an effective amount of an MDP equivalent, encapsulated in liposomes. The resulting composition is useful for reducing the severity and recurrence of HSV outbreaks.
Type:
Grant
Filed:
October 11, 1991
Date of Patent:
September 22, 1992
Assignees:
Board of Trustees of Leland Chiron Corporation, Stanford Junior University
Inventors:
Rodney Ho, Thomas Merigan, Rae L. Burke, Dino Dina